

Injection solution in a pre-filled Aranesp syringe is indicated for:
Active ingredient: Darbepoetin Alfa;
Each prefilled syringe contains Darbepoetin Alfa - 30 μg in 0.3 ml (100 μg / ml).
Excipients: sodium chloride, sodium dihydrogen phosphate monohydrate, sodium phosphate anhydrous, polysorbate 80, water for injection.
Hypersensitivity to darbepoetin alfa, r-HuEPO or to any of the excipients.
Arterial hypertension, which is not amenable to adequate drug control.
Treatment takes place only under the supervision of a doctor with experience in treating the above indications.
Aranesp is supplied ready to use in pre-filled syringes. Instructions for use, handling and disposal are provided in the section.
Not assigned.
Aranesp can be prescribed to children from 11 years old.
Does not affect.
Even at very high serum levels, no symptoms of overdose were observed.
In case of polycythemia Aranesp should be temporarily discontinued. In the presence of clinical indications, phlebotomy can be performed.
Severe allergic reactions have been reported, including anaphylactic reactions, angioedema, allergic bronchospasm, skin rash and urticaria, which have been associated with Darbepoetin Alfa.
The clinical results obtained so far do not indicate any interaction of Aranesp with other substances. However, there is a potential for interaction with drugs that bind to a high degree to red blood cells, for example, cyclosporin, tacrolimus. If darbepoetin alfa is used simultaneously with any of these drugs, you should monitor the levels of these drugs in the blood and adjust the dose with an increase in hemoglobin concentration.
Store in the refrigerator (2 ° C - 8 ° C). Do not freeze.
Store in the original packaging to protect from light.
Keep out of the reach of children.
Shelf life is 2 years.